

Eduard Parellada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7722560/publications.pdf>

Version: 2024-02-01

71
papers

2,654
citations

172457

29
h-index

197818

49
g-index

76
all docs

76
docs citations

76
times ranked

3115
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. <i>British Journal of Psychiatry</i> , 2009, 194, 434-438.	2.8	224
2	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. <i>International Clinical Psychopharmacology</i> , 2005, 20, 121-130.	1.7	105
3	Risperidone in the Treatment of Patients With Delirium. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 348-353.	2.2	95
4	Progressive gray matter changes in first episode schizophrenia: A 4-year longitudinal magnetic resonance study using VBM. <i>Schizophrenia Research</i> , 2009, 114, 136-143.	2.0	94
5	Telomere Length and Pulse Pressure in Newly Diagnosed, Antipsychotic-Naive Patients With Non-affective Psychosis. <i>Schizophrenia Bulletin</i> , 2009, 35, 437-442.	4.3	92
6	Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 1994, 55, 131-139.	1.8	89
7	Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. <i>Journal of Psychopharmacology</i> , 2005, 19, 5-14.	4.0	88
8	Glucose abnormalities in the siblings of people with schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 110-113.	2.0	84
9	Regional cerebral blood flow pattern in normal young and aged volunteers: a99mTc-HMPAO SPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1329-1337.	2.1	81
10	Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre. <i>Journal of Affective Disorders</i> , 2021, 282, 26-32.	4.1	76
11	Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with non-affective psychosis. <i>Schizophrenia Research</i> , 2012, 134, 16-19.	2.0	74
12	Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 689-701.	5.9	67
13	Manic Syndrome Associated with Efavirenz Overdose. <i>Clinical Infectious Diseases</i> , 2001, 33, 270-271.	5.8	57
14	Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> , 2007, 191, 805-811.	3.1	57
15	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. <i>Neurology</i> , 2021, 97, e61-e75.	1.1	54
16	Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 58, 1-7.	4.8	52
17	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2009, 9, 404-410.	2.0	50
18	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 71-77.	4.8	47

#	ARTICLE	IF	CITATIONS
19	Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. <i>Translational Psychiatry</i> , 2021, 11, 271.	4.8	46
20	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. <i>Schizophrenia Research</i> , 2007, 90, 115-122.	2.0	45
21	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014, 48, 94-101.	3.1	45
22	Cannabis use and age of diagnosis of schizophrenia. <i>European Psychiatry</i> , 2009, 24, 282-286.	0.2	41
23	The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients. <i>Biological Psychiatry</i> , 1998, 44, 787-790.	1.3	40
24	Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. <i>Psychopharmacology</i> , 2005, 181, 401-406.	3.1	40
25	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. <i>Psychiatry Research</i> , 2009, 165, 175-180.	3.3	38
26	Testosterone in Newly Diagnosed, Antipsychotic-Naive Men With Nonaffective Psychosis. <i>Psychosomatic Medicine</i> , 2011, 73, 643-647.	2.0	38
27	CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 807-811.	1.9	36
28	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012, 12, 255-259.	2.0	35
29	A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. <i>Clinical Therapeutics</i> , 2014, 36, 1372-1388.e1.	2.5	35
30	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. <i>Journal of Clinical Medicine</i> , 2019, 8, 586.	2.4	31
31	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2015, 5, e626-e626.	4.8	30
32	Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. <i>Journal of Psychopharmacology</i> , 2008, 22, 882-894.	4.0	29
33	Fluorodeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic auditory activation. <i>Nuclear Medicine Communications</i> , 2008, 29, 894-900.	1.1	29
34	18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 69-76.	3.2	29
35	Differential brain glucose metabolic patterns in antipsychotic-naive first-episode schizophrenia with and without auditory verbal hallucinations. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 312-321.	2.4	29
36	Screening for substance use disorders in first-episode psychosis: Implications for readmission. <i>Schizophrenia Research</i> , 2013, 146, 125-131.	2.0	29

#	ARTICLE	IF	CITATIONS
37	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [¹²³ I]IBZM SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 87-97.	1.8	28
38	Clinical experience and management considerations with long-acting risperidone. <i>Current Medical Research and Opinion</i> , 2006, 22, 241-255.	1.9	27
39	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. <i>European Psychiatry</i> , 2020, 63, e71.	0.2	27
40	Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers. <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 67-74.	1.8	26
41	Brain Metabolism during Hallucination-Like Auditory Stimulation in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e84987.	2.5	25
42	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. <i>Neurology</i> , 2022, 98, .	1.1	25
43	Metabolic syndrome or glucose challenge in first episode of psychosis?. <i>European Psychiatry</i> , 2017, 41, 42-46.	0.2	22
44	Lack of sex differences in striatal dopamine D2 receptor binding in drug-naïve schizophrenic patients: an IBZM-SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2004, 130, 79-84.	1.8	21
45	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. <i>Neuropsychobiology</i> , 2008, 58, 65-70.	1.9	21
46	Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	1.7	20
47	Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review. <i>Patient Preference and Adherence</i> , 2015, 9, 695.	1.8	19
48	Striatal dopamine D 2 receptor density in neuroleptic-naïve and in neuroleptic-free schizophrenic patients: an ¹²³ I-IBZM-SPECT study. <i>Psychopharmacology</i> , 2004, 172, 165-169.	3.1	18
49	Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-3.	1.5	18
50	Network analysis of gene expression in peripheral blood identifies mTOR and NF- κ B pathways involved in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2015, 15, 452-460.	2.0	18
51	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010, 175, 173-175.	3.3	17
52	ARVCF single marker and haplotypic association with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1064-1069.	4.8	15
53	Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model. <i>Journal of Psychiatric Research</i> , 2019, 115, 29-35.	3.1	15
54	Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. <i>International Clinical Psychopharmacology</i> , 2010, 25, 149-154.	1.7	13

#	ARTICLE	IF	CITATIONS
55	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. <i>European Neuropsychopharmacology</i> , 2011, 21, 294-299.	0.7	12
56	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2017, 95, 91-101.	3.1	12
57	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 741-747.	1.9	11
58	A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 79-84.	1.8	11
59	Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders. <i>International Clinical Psychopharmacology</i> , 2018, 33, 15-33.	1.7	11
60	Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. <i>Psychopharmacology Bulletin</i> , 2007, 40, 82-100.	0.0	11
61	A continuous emotional task activates the left amygdala in healthy volunteers: 18FDG PET study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 199-206.	1.8	10
62	Treatment of Narcolepsy Complicated by Psychotic Symptoms. <i>Psychosomatics</i> , 2009, 50, 427-428.	2.5	9
63	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. <i>Journal of Psychiatric Research</i> , 2020, 126, 8-18.	3.1	9
64	Hypophyseal response to ECT: A higher and faster vasopressin peak. <i>Biological Psychiatry</i> , 1993, 33, 670-672.	1.3	5
65	Antipsychotic Treatment in a Patient With Schizophrenia Undergoing Hemodialysis. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 92-94.	1.4	4
66	Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report. <i>Actas Españolas De Psiquiatría</i> , 2017, 45, 248-55.	0.1	4
67	Left amygdalar activation in deficit syndrome compared with non-deficit subjects with schizophrenia during the control task in a facial emotion recognition paradigm. <i>Psychiatry Research - Neuroimaging</i> , 2012, 203, 109-110.	1.8	3
68	Plasma levels of oral risperidone during enteral nutrition in a pregnant schizophrenic patient. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 133-137.	2.7	2
69	An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 191-199.	2.4	2
70	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S157-S158.	4.3	0
71	Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report. <i>European Journal of Psychiatry</i> , 2012, 26, 169-173.	1.3	0